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EDITORIAL
Abstract— Hard-to-heal wounds continue to be a challenge
in the everyday surgical practice. Their treatment is time-
consuming, expensive and in many cases requires interdisci-
plinary assessment. Therapy option include properly selected
surgical procedures and dressings combined with systemic
antibiotherapy. Application of vacuum assisted closure (VAC)
facilitates the evacuation of pathological discharge, reduces
tissue oedema and eliminates bacterial biofilm. Complementary
administration of antibiotics to control chronic infection relies
today in most cases on vancomycin, ciprofloxacin or piperacillin
with tazobactam, with good clinical effect.
An alternative to antibiotics against MRSA, administered
at hospitals might be dalbavancin, a new generation lipogly-
copeptide, which belongs to the same class as vancomycin.
Introduction of dalbavancin and VAC might be an alternative
to traditional methods of therapy.
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I. Epidemiology
EXTENSIVE hard-to-heal wounds represent a significantproblem in everyday surgical practice. Despite many
years of experience and a number of therapeutic standards
effective cure is time-consuming, expensive and in many
cases requires interdisciplinary involvement. Progress of sur-
gical techniques over the last decades has contributed to an
increase in total healing rate, however there is a large group
of patients for whom lack of proper tissue regeneration leads
to chronic organ dysfunction.
Hard-to-heal wounds are referred to as so-called “silent
epidemic” which affects, according to various estimates,
even 1-2% of the population in developed countries. In
the US, the total number of patients hospitalized for this
reason amounted to nearly 6.5 million and the total cost of
treatment consumed 25 billion dollars. On the other hand,
in Scandinavian countries, spending related to the treatment
of chronic wounds accounts for 2-4% of the health care
budget.1, 2
Multicenter experiences indicate that dealing with chronic
wounds calls for a comprehensive approach and requires
a holistic assessment of the problem. Adequate treatment
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strategy depends on the improvement of local conditions as
well as on the general condition of the patient. Preventing in-
fection and keeping the injured tissue in moist setting became
the basic priorities.3 The key issue is to separate the heal-
ing area from potential sources of pathogens, i.e. necrosis,
gangrene or digestive contents in case of abdominal fistulas.
Simultaneous coexistence of chronic diseases deteriorates
general condition and additionally depletes the regenerative
potential of damaged tissue. Cardiovascular, metabolic or
renal failure as well as immunodeficiency syndromes can be
a potential trigger responsible for worse healing. Other risk
factors include older age, male sex, chronic steroid therapy,
nicotinism and malnutrition. All but the first two can be
modified in the course of treatment.1, 4
II. Pathogenesis of wound formation
However the pathophysiology of chronic wounds proves
that lack of healing depends on many factors, three of them
are crucial: local ischemia, infection and tissue swelling
strongly inhibit wound regeneration. Most complicated cases
are characterized by both synergy of these agents and their
mutual enhancement. Following the microcirculation insuffi-
ciency, local inflammation and swelling occurred. Insufficient
fluid supply and lack of gas diffusion facilitate bacterial
colonization initiated primarily by opportunistic pathogens.
As a consequence, necrosis is formed penetrating the skin,
subcutaneous tissue and even deeper located structures. In
addition pathological discharge accumulates on the bottom
of the wound which additionally impairs its effective re-
pair.5, 6 The growth and survival of microorganisms within
the infected area is stabilized by formation of a biofilm
defined as a bacterial matrix supplemented by polymers
(polysaccharides, proteins) and nucleic acids. It creates a
local microenvironment that facilitates bacterial adhesion and
protects colonies against adverse external factors including
loss of moisture. In addition, it is a medium for signal
transmission, transferring information responsible for drug
resistance6, 7
The resorption of biofilm is crucial in the process of
wound healing. As a barrier factor it hinders diffusion of
respiratory gases and neutralizes penetration of antiseptics
or anti-inflammatory solutions. By keeping the pH relatively
stable, biofilm supports the electrochemical gradient and, due
to its spatial structure, allows for the growth of both aero-
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bic and anaerobic bacteria. In hard-to-heal chronic wounds
biofilm is constantly regenerated with reimplantation after
2-3 days from its primary removal. This property explains
why current healing concepts recommend as a priority the
permanent removal of pathological exudate from the surface
of an infected wound.7, 8
III. Clinical management
The evaluation of wound healing is carried out through
clinical observation focusing on detection of hematoma and
inflammatory or purulent discharge. The next step is to
surgically examine the wound edges and fundus in search
of infected or necrotic tissues. Furthermore, if necessary, a
culture is collected as well as inflammatory markers in blood
serum are monitored which allows to control the effectiveness
of treatment or gives an early sign that the local infection
starts to develop into sepsis.9, 10
Wound treatment includes properly selected surgical pro-
cedures combined with systemic therapy. The key is me-
chanical debridement of the wound edges with removal of
any pathological discharge or necrotic changes and use of
appropriate antibacterial prophylaxis or even, if valuable,
antibiotic therapy. Treatment of hard-to-heal injuries carries
the risk of septic complications, therefore in addition to
surgical procedure the use of selected systemic antibiotic
should be considered. Crucial is not only the antibacterial
effect of a given substance, but also the mechanism of its
distribution that determines the effectiveness of penetration
in the healing site. Final decision should be based on the
antibiogram and must comply with clinical practice and local
guidelines.9, 11
IV. Hard–to—heal wounds and NPWT
One of the key achievements of the last decade in the
field of hard-to-heal wound therapy was the use of negative
pressure as a factor able to accelerate tissue regeneration.
NWPT (Negative-pressure wound therapy) or VAC (vacuum-
assisted closure) is done by placing a special polyurethane
sponge with a hole diameter of 500 to 600 µm inside the
wound and covering it with foil. Finally negative pressure is
generated within the dressing reaching the value from -50 to
-200 mmHg.12
VAC therapy results in the separation of pathological
discharge and reduction of residual edema. Decompression of
tissues significantly improves blood perfusion and lymphatic
drainage. Negative pressure effectively helps to eliminate
biofilm and inhibits also its new formation. As a result of
contraction of intercellular spaces and following reduction
of wound surface the use of a vacuum leads to so-called
micro- and macrodeformation. VAC therapy restricts local
inflammation, reduces tissue hypoxia and boosts cell prolif-
eration.13, 14
Some authors also suggest its beneficial antibacterial ef-
fect, especially the limitation of Gramm-negative germs
growth. Application of negative pressure favors the me-
chanical elimination of bacterial cells and also improves
local pharmacodynamic and pharmacokinetic features of drug
penetration.14
In practical terms the effectiveness of vacuum therapy is
mainly determined by two elements, i.e. the value of the
generated under-pressure and its proper distribution. The
value of pressure advisable in the literature ranges from -
50 to -200 mmHg and depends on the type of wound, its
location, dimensions and the degree of tissue damage. It is
generally accepted that pressure from -80 to - 125 mmHg is
a compromise between sufficient removing of pathological
discharge and the potential mechanical destruction of the
wound surface. The problem of proper pressure distribution
within the dressing is still the subject of research. There
is no answer to the question about the possible difference
between the value of pressure detected on the generator and
its real value in different parts of dressing. The advantage
of commonly used systems is the ability to individually
adjust the sponge to the shape of the wound. Thereby
the dressing covers the entire surface of the wound and
protects it from the outside environment. Finally, the NPWT
significantly minimizes the need for hospitalization, enabling
further treatment in outpatient clinic.15, 16
V. NPWT vs antibiotherapy
There are a number of studies evaluating the effectiveness
of systemic antibiotic therapy used jointly with negative
pressure therapy in the treatment of complicated wounds. The
results of many analyses, although based on a relatively small
group of cases, indicate that NPWT augments the therapeutic
activity of intravenous injection. Rowan et al. Assessing
the efficacy of vancomycin, ciprofloxacin, and piperacillin
with tazobactam in the treatment of hard-to-heal wounds
showed that by using a vacuum dressing, the concentration
of antibiotic within the wound reaches a value of not less
than 80% of plasma concentration.11
The beneficial interaction of NPWT with systemic an-
tibacterial treatment prompts to define a clinical algorithm
allowing more effective use of both methods of therapy,
especially in outpatient care. In this context, dalbavancin,
a lipoglycopeptide antibiotic classified to the same group as
vancomycin can increase the efficiency of wound healing.
In preliminary clinical trials dalbavancin has been shown to
be highly effective in the treatment of acute skin and soft
tissue infections, including the elimination of methicillin-
resistant S. aureus (MRSA). An additional advantage is its
unique pharmacodynamic profile limiting the dosage for
single administration or in two doses repeated one week
apart.11, 17
VI. Conclusion
In conclusion a strategy based on surgical debridement,
followed by NPWT and a single dose of dalbavancin in
prophylaxis and therapy may be beneficial in a treatment of
complicated wounds.However final recommendation requires
further evaluation in a wider group of patients.
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